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BACKGROUND. In recent years, there has been an increasing interest in targeting human
prostate tumor-associated antigens (TAAs) for prostate cancer immunotherapy as an
alternative to other therapeutic modalities. However, immunologic tolerance to TAA poses a
significant obstacle to effective, TAA-targeted immunotherapy. We sought to investigate
whether androgen deprivation would result in circumventing immune tolerance to prostate
TAA by impacting CD8 cell responses.
METHODS. To this end, we generated a transgenic mouse that expresses the human prostate-
specific antigen (PSA) specifically in the prostate, and crossed it to the HLA-A2.1 transgenic
mouse to evaluate how androgen deprivation affects human HLA A2.1-resticted T cell
responses following immunization of PSA-expressing mice by vaccinia-PSA (PROSTVAC).
RESULTS. Our PSA transgenic mouse showed restricted expression of PSA in the prostate and
detectable circulating PSA levels. Additionally, PSA expression was androgen-dependent with
reduced PSA expression in the prostate within 1 week of castration, and undetectable
PSA by day 42 after castration as evaluated by ELISA. Castration of the PSA/A2.1 hybrid
mouse prior to immunization with a PSA-expressing recombinant vaccinia virus resulted in a
significant augmentation of PSA-specific cytotoxic lymphocytes.
CONCLUSIONS. This humanized hybrid mouse model provides a well-defined system to
gain additional insight into the mechanisms of immune tolerance to PSA and to test novel
strategies aiming at circumventing immune tolerance to PSA and other TAA for targeted
prostate cancer immunotherapy. Prostate 70: 1002–1011, 2010. # 2010 Wiley-Liss, Inc.
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INTRODUCTION
To date, clinical trials of PCa immunotherapy
included immunization with defined antigenic pre-
parations such as synthetic peptides [1–3], antigen-
[4,5] or mRNA-loaded dendritic cells [6], manipulated
tumor cells [7], or with plasmid DNA [8] or viral
vectors engineered to express immunogenic genes
[9]. In particular, recombinant vaccinia virus expres-
sing prostate-specific antigen (PSA) was tested in
clinical trials in combination with recombinant PSA-
expressing fowlpox virus [10,11], demonstrating its
ability to trigger a specific immune response [11] and
an 8.5-month improvement in median overall survival
in men with metastatic castration-resistant prostate
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cancer [10]. However, the survival benefit remains
modest, suggesting an opportunity and need for
significant improvement of efficacy in PCa immuno-
therapy.
In 1999, a study reported combined immunization
with androgen deprivation to modulate antigen
expression as a means of circumventing tolerance to a
prostate tumor-associated antigen (TAA)-specific in
the setting of a human PCa clinical trial that targeted
PSA as a prototype PCa TAA [12]. The scientific
basis for combining androgen deprivation and PCa
TAA-specific immunization was subsequently vali-
dated in mouse models that focused on MHC class II-
mediated helper T cell responses [13,14]. Androgen
ablation results in a rapid involution of benign and
neoplastic prostate tissue at both primary and meta-
static sites, seemingly because of apoptosis of andro-
gen-dependent epithelial cells [15–17]. This treatment
has been shown to induce infiltration of lymphocytes,
macrophages and dendritic cells into the prostate and
trigger inflammation [18]. Such infiltration proved to
be beneficial for PCa immunotherapy as it provides a
synergistic help by increasing the number of tumor
antigen-specific lymphocytes [13,19,20]. Additional
supporting evidence for this concept was provided by
the demonstration that testosterone can be immuno-
suppressive by stimulating tumors to secrete TGF-b, a
cytokine that promotes the expansion of Treg [21].
Androgen deprivation has been shown to result in a
decrease in expression of these genes in both patients
undergoing androgen ablation therapy and in human
PCa cell lines [22]. In mice, androgen deprivation-
induced TAA gene downregulation has been shown to
circumvent immune tolerance and enhance CD4 T cell
responses to prostate TAA [13]. However, the effect
of androgen deprivation on the generation of TAA-
specific CD8 T cells has not been addressed before.
In this report, we describe the initial characterization
of transgenic mice expressing the PSA transgene in an
androgen-regulated and prostate-specific manner. To
further refine current prostate cancer models, we
developed a unique double-transgenic mouse model
co-expressing PSA and HLA-A2.1 to facilitate the
investigation of PSA-specific tolerance in the context
of human MHC. Finally, we sought to determine
whether castration of male mice prior to immunization
to PSA improves class I MCH-restricted T cell
responses to this clinically relevant target antigen.
MATERIALSANDMETHODS
Peptides,Proteins andViruses
Previously described HLA-A2.1-restricted, PSA-
derived peptide PSA-3 (VISNDVCAQV) and its agonist
PSA-3A (YISNDVCAQV) [23] and the H-2Kb restricted-,
SV40 Tag-derived Tag-IV peptide (VVYDFLKC) [24,25]
were purchased from the Macromolecular Resources
Facility at Colorado State University (Ft. Collins, CO).
Human PSA was purchased from Calbiochem (San
Diego, CA). Vac-PSA was obtained from Therion
Biologics Corporation (Cambridge, MA). Vac-mTag
was generated in our laboratory [26–28].
Generation of Transgenic rPB-PSAMice,
Construction of PSATransgenicMap
Human prostate-specific antigen (PSA) prepro-
cDNA (accession no. M26663, NID g618463) was
ligated to rat probasin (rPB) promoter cassette
(GI:10000942, 426 to þ28) [29] at the introduced
BamH1 site. The rPB-PSA was ligated to a bovine
growth hormone (bGH, GI:2168498, 1,872–2,028)
terminator sequence at the BglII site. The final rPB-
PSA transgene construct was microinjected into
oocytes of foster mouse mothers and offspring were
evaluated by PCR using PSA primers. The transgene
transmission to the progeny of potential founder
mice was verified by PCR and Southern blot. From
among several candidate founders we have generated,
the mouse expressing stably the highest levels of PSA as
detected by ELISA was selected as the founder to
propagate hybrid transgenic colonies.
The rPB-PSA transgenic map was constructed to
confirm boundary sequences between the rat probasin
promoter region, PSA open reading frame (ORF)
and the bGH terminator. Primer sets located in the
promoter-PSA and PSA-terminator flanking regions
were designed and utilized to generate overlapping




Hybrid PSA and HLA-A2.1 double transgenic
mice (PSA/A2.1) were generated by cross-breeding
PSA mice with HLA A2.1/H2Kb transgenic mice
(Harlan Sprague Dawley, Indianapolis, IN). All double
transgenic mice were heterozygous for each of their
transgenes as confirmed by PCR.
Genotypingof PSATransgenicMice
Tail snippets from 3-week-old transgenic mice were
collected and their DNA isolated. PCR was used to
genotype transgenic progeny using the following PSA
primers (Invitrogen):
PSA-FOR: 50 ACCATGTGGGTCCCGGTTG 30 and
PSA-REV: 50 TCAGGGGTTGGCCACGATG 30.
The Prostate
AndrogensModulate Prostate Cancer Immunity 1003
DNA quality was tested with a b-globin PCR
performed concurrently in each of the PSA reactions
using the following primers: FOR: 50 GCCAATCTGCT-
CACACAGGATA 30 and REV: 50 CATGCAGCTTGT-
CACAGTGGA 30.
PCR reactions contained 200–300 ng of genomic
DNA template, 10 mM Tris/HCl pH 8.3, 50 mM KCl,
200 mM dNTPs, 1 mM each of forward and reverse
primers, 1.25 U Taq DNA polymerase (Applied Bio-
systems) and 1.5 mM MgCl2 in a 25 ml final reaction
volume. PSA-b-globin PCR was performed using PSA
and globin primers in 25 ml reaction at 948C, 3 min
followed by 30 cycles of 948C for 1 min, 558C for 1 min,
728C for 2 min, and final elongation at 728C for 10 min.
Samples were stored at 48C until gel electrophoresis
was performed using a 1% agarose gel in 1 TAE
buffer.
Extraction of RNAandRT-PCR
Total RNA was isolated from the prostate and other
tissues using the Nucleospin RNA II Kit (Clontech,
Mountain View, CA). RT-PCR was performed using a
reverse transcriptase kit (Promega, Madison, WI).
PSA primers were as described above, and b-actin
primers that were used for control reactions as follows:
b-actin FOR: 50 TGTGATGGTGGGAATGGGTCAG
30and REV: 50 TTTGATGTCACGCACGATTTCC 30. A
parallel RT-PCR reaction without reverse transcriptase
served as a negative control. PCR products were
visualized on a 1% agarose gel.
Castration of PSATransgenicMice
Mice were anesthetized with a ketamine–xylazine
mixture (ratio 90 mg/kg ketamine to 4.5 mg/kg xyla-
zine) administered i.p. A lower abdominal incision was
made, the testicular blood supply isolated and ligated
with electrocautery. The testes were removed and the
vasa cauterized. Mice were re-explored at various time
intervals (e.g. 7, 14, 21, 28, and 42 days) for harvesting of
tissues.
Quantitaion of PSALevelsby ELISA
Tissues were homogenized by mincing with surgical
blade, resuspend in equal volume of Buffer A (50 mM
Tris, KCl 1.15% pH 7.5) and Buffer C (10 mM KPO4,
0.25 mM Sucrose pH 7.4) (max volume of 500 ml), and
passed through a 21G needle with 1 ml of syringe. Cells
were sonicated at 30% output (180 W) for 10 sec
pulse (three times). The lysate was centrifuged at
13,000 rpm for 10 min at room temperature. The protein
concentration in the supernatant was calculated using
the Bio-Rad protein assay kit (Bio-Rad Laboratories,
Hercules, CA). 120 ml of lysate containing 50 mg of
protein was used for PSA ELISA. Serum PSA concen-
tration was measured by AxSYM PSA assay (AxSym
system, Abbott Diagnostics, Abbott Park, IL), a Micro-
particle Enzyme Immunoassay designed to quantitate
PSA levels in human serum.
One hundred micrograms of total protein was
placed in 250 ml of clear Hanks balanced salt solution
and samples were submitted to the University of
Michigan clinical pathology laboratory for PSA ELISA.
Samples consisting of purified PSA from human
semen or protein from wild type C57BL/6 mice were
submitted to serve as positive and negative controls,
respectively.
MouseWhole Blood Processing and
HLAA2.1/Kb FACSAnalysis
One hundred microliters of blood was obtained from
each mouse via orbital puncture and placed in a
heparinized microfuge tube. Blood was placed in 2 ml
lysis buffer (Mouse Erythrocyte Lysing Kit, R&D
Systems Inc.) for 10 min at room temperature. Samples
were centrifuged for 5 min at 250 g, the supernatant
was discarded, and the pellets were washed with 2 ml
of 1 PBS. One million peripheral blood cells were
incubated with 0.5 mg anti-mouse FcgR antibody
(Mouse Fc Block, BD PharMingen) for 10 min at 48C.
0.5 mg of FITC-conjugated anti-HLA A2 antibody (One
Lambda, Inc., Canoga Park, CA) or isotype control was
then added and the reaction mixture was incubated in a
final volume of 20 ml at 48C for 1 hr. Cells labeled
with isotype control were used to assess background
fluorescence, and 10,000 viable cells were analyzed
in a FACScan microflourometer (Becton Dickinson,
Sunnyvale, CA).
Immunization of Castrated PSA/A2.1
TransgenicMice
PSA/A2.1 mice were anesthetized with a ketamine–
xylazine mixture (ratio 90 mg/kg ketamine to 4.5 mg/kg
xylazine) administered i.p. A lower abdominal incision
was made, the testicular blood supply isolated, and
ligated with electrocautery. The testes were removed
and the vasa cauterized. Four weeks post-castration,
mice were immunized intravenously with 106 PFU of
a recombinant vaccinia virus expressing either the
entire sequence of PSA (vac-PSA) [30] or the modified
SV40 T antigen (vac-mTag) we previously generated in
our laboratory [26–28].
Generationof Bone-Marrow-DerivedDendritic Cells
Dendritic cells (DC) were generated from bone
marrow using IL-4 and GM-CSF (PeproTech, Rocky
Hill, NJ), and purified on a metrizamide gradient. DC
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maturation was evaluated by measuring MHC Class II,
CD11c, CD40, CD80, and CD86 surface expression.
Peptides (final 20 mg/ml) or proteins (50 mg/ml) were
loaded on DC at 378C for 4 hr or overnight, respectively.
Loaded DC were washed and used as antigen-
presenting cells in the ELISPOT assay.
IFN-gELISPOTAssay
MultiScreen 96-well plates were first coated with
purified anti-mouse IFN-g antibody (capture antibody)
(4 mg/ml in 1 PBS; PharMingen) overnight at 48C.
Plates were blocked with PBS/1% BSA (PBS-BSA) at
room temperature for 90 min and then washed thrice
with 1 PBS before seeding the cells. CD8þ T cells were
isolated from mice 3 weeks after immunization with
106 pfu/mouse vac-PSA or 107 vac-mTag. One million
CD8þ T cells were seeded into each well (E/S¼ 10) and
incubated at 378C/5% CO2 for 24 hr with irradiated
(5,000 rad) peptide- or protein-loaded DC. Plates were
washed thrice with 1PBS and then four times with 1
PBS/0.025% Tween-20 (PBS-TW20) before adding
biotin rat anti-mouse IFN-g antibody (2 mg/ml in PBS-
BSA; PharMingen) overnight at 48C. The plates were
washed four times with PBS-TW20 and incubated
with anti-biotin antibody (1:1,000 dilution; Vector;
Burtingame, CA) at room temperature for 90 min,
followed by washing four times with PBS. Plates were
then developed with NBT/BCIP before subjecting to an
ELISPOT reader (Cellular Technology Laboratories,
Ltd.; Cleveland, OH) to count spots.
RESULTS
Prostate-Specif|c, Androgen-Dependent
Expression of PSAin aTransgenicMouse
The rat probasin gene promoter has been demon-
strated to be both developmentally and hormonally
regulated in the mouse and demonstrates a high
ability to direct transgene expression specifically
to the prostate tissue [31]. The promoter has been
previously utilized to generate transgenic mice that
express viral [29] and human oncogenes [32,33] in
the prostate to study prostate cancer development. We
adopted a similar strategy to generate a transgenic
mouse that exhibits prostate-specific expression of
human PSA. To this end, an expression cassette
containing human PSA cDNA, the rat probasin
promoter, and the bovine growth hormone terminator
sequence (Fig. 1A) served to generate transgenic
founders. The founder that produced progeny that
had stable and high levels of PSA expression was
selected to propagate the colony.
To address the specificity of the PSA expression, we
isolated RNA from prostate, testis, seminal vesicle,
spleen, pancreas, liver, lung, and nodal tissue from
multiple progeny. Using RT-PCR, we confirmed that
the presence of RNA transcript for PSA was restricted
to the prostate tissue (Fig. 1B). In line with this finding,
analysis of protein extracts from these tissues by ELISA
detected PSA in the prostate but not in any of the other
tissues (Fig. 2A).
To test androgen-responsiveness of the PSA trans-
gene, mice were castrated and killed at various time
points, and the presence of PSA mRNA was tested by
RT-PCR. As shown in Figure 2B, expression of the
transgene decreased in a time-dependent fashion after
castration. Only a minimal expression was present
at day 28 post-castration, and no transcripts were
detected at day 42.
Generation of a PSA/HLA-A2.1HybridMouse
To generate a hybrid mouse that expresses both
human HLA-A2.1 and PSA, PSA and HLA A2.1/Kb
transgenic mice were crossed and the progeny tested by
PCR of genomic DNA (data not shown). Progeny that
possessed copies of both transgenes (data not shown)
were further tested for HLA-A2.1 expression by flow
cytometry. These double-positive mice demonstrated
expression of the HLA A2.1/Kb chimeric receptor on
peripheral blood lymphocytes as demonstrated by
FACS analysis. Some of these mice were killed and
protein extracts from mouse prostate tissue contained




Consistent with the known immunosuppressive
effects of androgens, castration of prostate tumor-
bearing mice has been shown to enhance antigen-
specific CD4 T cell responses to a model prostate TAA
[13]. We therefore sought to determine whether CD8
responses are affected by androgen deprivation using
the PSA/A2.1 as a model and PSA or PSA-derived
peptides as immunogens. Male A2.1 and female PSA/
A2.1 mice were used as controls.
Mice were immunized with recombinant vaccinia
virus constructs that express either PSA (vac-PSA) or
SV40 Tag (vac-mTag). Splenocytes from immunized
mice were re-stimulated in vitro with peptide- or full
protein-loaded dendritic cells and IFN-g-releasing CD8
T cells were quantitated by ELISPOT and tetramer
staining. Our data show that splenocytes from sham-
castrated male, castrated male, and female PSA/A2.1
mice immunized with vac-mTag responded in a
similar fashion to restimulation with Tag-IV, while no
response was observed with splenocytes from vac-PSA
immunized mice. A similar response to Tag IV was
The Prostate
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obtained in control vac-mTag-immunized A2.1 mice,
indicating a complete absence of tolerance to exoge-
nous antigen in these mice (Fig. 3A). Immunization
with vac-PSA resulted in a strong and specific response
in A2.1 mice upon re-stimulation with full PSA-
loaded DC. However, a very weak response was
observed in PSA/A2.1. Castrated mice responded
better (P< 0.001), although this response was still
significantly lower than male A2.1 and female PSA/
A2.1 mice (P< 0.001) (Fig. 3B). Splenocytes from
vac-PSA-immunized mice showed a much lower
number of IFN-g-releasing, PSA-specific CD8 T cells
upon re-stimulation with DC loaded with the peptides
PSA3A (Fig. 3C) and PSA3 (Fig. 3D). Such a weak
response to PSA peptides as compared with full PSA
protein is possibly because the contribution of H2-Db
to the response to potential H2-Db-restricted, PSA-
derived epitopes in this mouse model. Sham-castrated
male PSA/A2.1 showed no response, whereas
castrated mice showed a weak response. Because
of the overall signal to noise window for ELISPOT
evaluation of A2.1-restricted PSA peptide responses
(females vac-mTag controls showed low but significant
activity of PSA peptides, Fig. 3C and D), we turned to
tetramer assay to ascertain detection of A2.1-restricted,
PSA-specific CTL. To this aim, we labeled in vitro-
restimulated splenocytes with a PSA-3A-A2.1 tetramer
and used flow cytometry to determine the fraction of
CD8(þ) T cells that bound the tetramer. Consistent
with the ELISPOT data, tetramer staining revealed
elevated amounts of PSA-specific CD8 T cells in spleens
of immunized non-transgenic mice. These amounts
were significantly lower (comparable to background
level as seen in vac-mTag-immunized mice) in PSA
transgenic mice, reflecting a deep immune tolerance
to PSA. Splenocytes from castrated immunized male
The Prostate
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PSA/A2.1 mice exhibited significantly higher numbers
of tetramer-positive CD8 cells than did their non-
castrated counterparts. The effect of castration was
similar to the one observed in A2.1-PSA females, but
still lower than in A2.1 male mice (Fig. 4).
DISCUSSION
A large body of evidence suggests the feasibility of
PSA-based vaccines for prostate cancer [2,3,12,34–41].
However, because PSA is a self-antigen, these
vaccines face the challenge of immune tolerance to
PSA and are yet to demonstrate clinical efficacy.
Hence, immunotherapy for PCa will most likely
consist of combined approaches that simultaneously
target tumors through TAA and interfere with toleriz-
ing mechanisms that hinder immunity to tumors.
These mechanisms include innate and adaptive
immune responses, activation/inhibition of co-
stimulatory/inhibitory molecules (e.g., CTLA-4),
elimination of regulatory/suppressive cells (e.g., reg-
ulatory T cells—Treg) and soluble factors, and manip-
ulation of hormonal pathways. So far, interference
with the inhibitory co-stimulatory signals mediated by
CTLA-4 using monoclonal antibodies has provided the
most promising results, although a myriad of adverse
autoimmune responses generated by this strategy still
represent a sizeable obstacle to its implementation in
clinic (reviewed in Ref. [42]).
In prostate cancer, androgen deprivation is a
therapeutic modality that aims at depriving the
prostate from testosterone to suppress its growth.
Interestingly, this deprivation also results in strength-
ening immunity to tumors as shown in mice [13] and
humans [12]. The mechanisms whereby androgen
deprivation affects immunity to tumors are poorly
understood, partly because of the lack of appropriate
mouse models.
Although the impact of androgen deprivation on
prostate tumor immunity has been addressed in
previous work, these failed to look at the extent to
which CTL responses to a human prostate TAA are
affected in vivo in humanized mice.
In this work, we describe a transgenic mouse that
expresses human PSA specifically in the prostate.
Tissue-specific expression was demonstrated at both
RNA and protein levels. We additionally show that
expression of PSA in this mouse is regulated by
androgens, confirming an optimal performance of the
rat probasin promoter in this setting. This is evidenced
by a time-dependent decrease of PSA levels in castrated
male mice. At day 42 post-castration, no PSA was
detected.
We crossed the PSA transgenic mouse with HLA-
A2.1/Kb transgenic mouse. The resulting male off-
spring offers a valuable tool that allows investigation of
immune tolerance to a human prostate antigen in a way
that closely emulates human biology.
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Fig. 2. Androgen-regulated, prostate-specific expression of PSA.A: Prostate lysates from three differentmice (P719, P722,P748) showed
significant PSAlevels as comparedwith lysates fromother tissues/organs orprostate fromnon-transgenicmice.TissuePSAlevelsweredeter-
minedusingPSA-specificELISA.Data shownasmean SDfromthreeanimals.B:Expressionof thePSAtransgeneisandrogen-dependentand
tissuelevelsof theproteindecreasewithtimefollowing surgicalcastration.PSAmiceexhibithighlevelsofPSAexpressionandaresimilar toPSA
positivecontrols.Followingcastration,prostatelevelsofPSAfallandat28daysaresimilar tonon-transgenicmouseprostates.Onerepresenta-
tivemouseis shown.
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As expected, immunization of this hybrid mouse to a
non-self-antigen (SV40 Tag) resulted in a strong CTL
response, whereas only a very weak response was
generated towards a self-antigen (PSA). In contrast,
castration of male mice 4 weeks prior to immunization
resulted in a significant augmentation of CTL
response to PSA, while it did not affect the response
to SV40 Tag. Interestingly, female hybrid mice showed
a stronger response to PSA than did their castrated
male counterparts.
Although interference of castration with immune
tolerance to prostate specific antigens has been
reported in two previous studies [13,14], these
studies either focused on CD4 responses [13] or did
not show any effect of castration when applied before
immunization [14]. In the latter study, a prime-boost
immunization protocol was applied and immune
responses following primary immunization were not
evaluated.
Overall, our present work describes a PSA/A2.1
transgenic mouse that might represent an attractive
animal model to investigate immune tolerance to
human prostate TAA and for preclinical development
and refinement of PSA-targeted vaccines. It also
The Prostate
Fig. 3. CastrationofmalePSA/A2.1miceaugmentsPSA-specificcellularimmuneresponses.Castratedmalemicewereimmunizedwitheither
vac-mTag or vac-PSA and antigen-specific CD8 responses were evaluated by ELISPOTand tetramer staining.Non-castratedmale mice and
female mice were used as controls. For splenocyte restimulation in vitro, bone marrow-derived DC were loaded with either H-2Kb




provides compelling evidence supporting the use
of androgen deprivation as a modality to circumvent
immune tolerance to prostate TAA.
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